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Abstract Tumour genetics is currently turning into a massive clinical approach. This paper
is an enquiry into its practices as they expand beyond expert and experimental
contexts and become routinised in clinical hospital settings. Studying a French
university hospital, we unpack the content and everyday organization of diagnostic
labour in this context. Exploring the sociotechnical frictions that arise in the
process, we describe the ways in which they are collectively controlled, and
stabilized through organizational fictions, that are instrumental in making tumour
genetics doable in the hospital, at a large scale. We further show that the new role
of external regulations in the production of clinical values for mutations has a
strong impact on diagnostic work, making it possible to be performed locally
without resorting to expert bioclinical collectives, and outside the professional
jurisdiction of clinical geneticists. This division of labour appears as a necessary
condition for the rise in clinical productivity required by a new function assigned
to genetics: to guide the prescription of drugs for common diseases. This turn in
the way genetics is embedded in the clinic calls for a thorough reassessment of its
impacts on clinical discourses, practices and decisions.
Keywords: France, Tumour genetics, Biomedical platform, Diagnosis, Clinical genetics,
Targeted therapy, INCa, Routine
Introduction
Oncology has long been a field of interest in social science for studying how ‘new genetics’
impacts clinical discourses, practices and decisions. Though concerning only a minority of
patients affected by cancers, oncogenetics is one of the most active fields for clinical genetic test-
ing, far ahead from the majority of other rare genetic diseases. With the rise of targeted therapies,
a new mode of genetic analysis – tumour genetics – has entered the field of oncology. This
approach contrasts with oncogenetics on two levels: first, its target of analysis is not an individ-
ual’s germline DNA, but her tumour’s DNA. Second, a mutation is no longer understood as the
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molecularised inscription of a clinical lesion (Foucault 1963, Gaudilliere 2002) but as a trace of
the tumoural process, signalling a putative response to a particular drug. The types of cancers
concerned are numerous – including lung, colorectal, stomach, ovarian, breast cancers, mela-
noma or leukaemia – and the number of potentially eligible cases is growing. As a result, tumour
genetics is turning into a massive practice: in 2016 in France, 83,000 patients had their tumours
genetically profiled whereas 38,000 underwent an oncogenetic test.
In this paper, we aim at characterizing the organization of tumour genetics practices as they
expand beyond expert and experimental contexts, and become routinised in clinical hospital
settings, i.e. institutions with a higher pressure for clinical productivity and a more limited
connection to research. As many researchers of technological innovation in healthcare have
demonstrated (e.g. Beaudevin and Pordie 2016, Lock et al. 2000), final uses of a technology –
whether mainstream and compliant or ‘diverted’ and unsanctioned – are shaped in crucial ways
by social and clinical contexts. Routine practices of tumour genetics cannot be understood as
mere adaptations of pre-existing arrangements. Rather, they are embedded in a different field
of constraints, are organized primarily to meet everyday hospital needs, and are mostly freed
from pre-defined technological expectations. Drawing on a collective ethnography, we study
the case of a ‘tumour molecular genetics platform’ set in a French university hospital, where
the analyses required for delivering new targeted therapies against metastatic cancers are rou-
tinely performed. We unpack the content and everyday organization of the diagnostic labour
being performed, describing how actors deal with issues such as: the articulation of DNA
sequencers, patient records and kraft envelopes; the practical differences between tumour
genetics and ‘true genetics’; or the validity of a tumour analysis report.
Our contribution aims at showing that in this routine hospital setting, no ‘bioclinical collective’
(Rabeharisoa and Bourret 2009) is locally mobilized to perform the clinical work and produce
the meaning and relevance of mutations. Because external regulations, including market autho-
rizations and guidelines, define the mutations searched for in the tumours, the diagnostic labour
can be further divided, and the diagnoses can be performed outside the professional jurisdiction
(Abbott 1988) of clinical geneticists. This reorganization of diagnostic labour, as well as the
dynamics of circulation of funds, artefacts and information that characterize the platform make
the scaling up of tumour genetics possible: they indeed allow the routine management of signifi-
cant numbers of genetic analyses by professionals with a more fragmented expertise.
We begin by presenting how the advent of ‘new genetics’ in the clinic – and especially geno-
mic testing for mutations in tumour cells – has been framed and discussed within social science.
This allows us to emphasize the way our research is both linked to, and differs from, the thematic
and theoretical interests explored within the sociological literature on ‘biomedical platforms’. We
then present our case study, and report on its main findings. First, we suggest that tumour genet-
ics – when analysed as a form of molecular medicine being introduced into a hospital’s routine –
does not appear to grow out of the traditional sites and practices of clinical genetics: it emerges
in a neighbouring but specific space. Second, we explore the frictions – professional, technologi-
cal and otherwise – that arise in the process. We show how these frictions are collectively con-
trolled, and stabilized through organizational fictions, that are instrumental in making the routine,
large-scale use of tumour genetics in the hospital doable. This in turn participates in constructing
a new representation of genetics: faster and relevant to a much larger part of the population.
Biomedical platforms and diagnostic labour in the clinic
In recent years, an important body of work dealing with the introduction and use of genetic
theories and technologies in clinical contexts has emerged. Social scientists have devoted much
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attention to grappling how, and to what extent, ‘new genetics’ impacts clinical discourses,
practices and decisions. In his empirical exploration of the ‘geneticisation’ thesis propounded
by Lippman (1991, 1992), Hedgecoe (2003) describes how, in the context of rare diseases
such as cystic fibrosis, genetic explanations become dominant in the clinical space, and play
an important role in reconfiguring the classification of diseases and medical practices. How-
ever, as has been pointed out by others (see Weiner et al. 2017 for a thorough review), one of
the main shortcomings of the ‘geneticisation’ framework resides in its overly simplistic view
of how genetic reductionism is mobilised to legitimate a biologically deterministic understand-
ing of individuals and pathologies. The framework does not pay enough attention to the
sociotechnical mediations required for molecular knowledge to affect nosology, diagnosis and
care. Conversely, it underestimates the open-ended, uncertain nature of this process, as well as
the active role played in it by clinicians, patients, scientists and technicians – resulting in a
skewed representation of the complex interplay between genetic diseases and molecular genet-
ics, as well as between genetic testing, categorical work and clinical judgement (Kerr 2004,
Latimer 2015, Latimer et al. 2006).
In many ways, Keating and Cambrosio’s seminal study of Biomedical Platforms and their
subsequent work also challenges this narrative of geneticisation, especially in the field of
oncology. Their account of how the cluster of differentiation system was devised and used
within immuno-phenotyping platforms as cell-surface markers for the diagnosis of leukaemia
is informed by a description of biomedical platforms as ‘specific combinations of techniques,
instruments, reagents, skills, constituent entities [. . .], spaces of representations, diagnostic,
prognostic, and therapeutic indications, and related etiologic accounts’. More analytically,
they define biomedical platforms as ‘material and discursive arrangements that act as the
bench upon which conventions concerning the biological or normal are connected with con-
ventions concerning the medical or pathological’ (Keating and Cambrosio 2003, 4). In this
framework, clinical knowledge and practices are at least as crucial to the constitution of new
genetics as their biological counterpart. Furthermore, the agency of artefacts and conventions
in the production of contemporary biomedicine is foregrounded here, platforms appearing as
the crucibles in which novel biomedical entities are forged. This analytical model insists on
the pre-eminence of biomedical platforms in the generation, maintenance and transformation
of the sociotechnical networks through which coordination is achieved in biomedicine: ‘plat-
forms supply networks with conventions, generate novel entities, and entrench them in clini-
cal routines’ (Id., 324). The authors argue that this is made possible by intense regulatory
work – regulation being understood here in a broad sense, including not only public inter-
vention through regulatory agencies, but also ‘de facto, informal, and even tacit agreements,
standards, and guidelines’ (Id., 258). Regulation therefore includes elements such as categori-
cal work around diagnostic nomenclatures, or the professional and organizational rules that
frame activities.
Building upon this framework, Rabeharisoa and Bourret (2009) argue that these forms of
regulatory work involving biomedical entities extend far beyond the research laboratory, and
permeate clinical activity itself. They suggest that contemporary genetics-inflected clinical
practices (as found for example in oncology and psychiatry) are subjected to a three-fold trans-
formation: the emergence of multidisciplinary ‘bioclinical collectives’ that collaborate across
biology and pathology; a change in the content of clinical work, giving rise to what they dub
‘clinic of mutations’, in which bioclinical collectives ‘are led to explore and test the clinical
relevance and biological nature of mutations’ (Id., 701); and finally, a growing overlap
between clinical work and research, since medical judgement and decisions are no longer con-
fined to diagnosis or prognosis, but encompass the ‘testing and invention [. . .] of descriptive
and interpretive models that give meaning to mutations and to their complex relations with
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heterogeneous elements that may be involved in the development of [. . .] diseases’ (Id., 709).
Their analysis thus reflects that, far from fostering reductionism, ‘genetics reinforces the com-
plexity of pathological categories’ (Id., 697) and affects the nature of clinical work itself.
More recent scholarship by these researchers and their collaborators draws upon the same
analytical framework to characterize the impact of genomic testing in tumour cells on clinical
activity. These studies (especially Bourret et al. 2011, Nelson et al. 2013, 2014) reflect on
how diagnosis, prognosis and therapeutic decisions are reconfigured by the introduction of
sequencing technologies in clinical settings. They consistently highlight three key features: the
growing experimentalisation of clinical work, especially through new kinds of clinical trials
that link biological evidence to clinical characteristics; the increasingly collective nature of
clinical judgement and clinical decision-making; and the role played by different forms of
regulatory work in these processes.
Our own investigation is thematically and theoretically related to many of the questions
raised and explored by these researchers. We too are interested in understanding the sociotech-
nical mediations through which tumour genetics becomes integrated into clinical work. How-
ever, the focus of our contribution and our perspective are distinct in some important respects.
Our analysis is grounded in the ethnography of the clinical work that takes place in the com-
plex inter-organizational setting of a routine hospital platform for molecular genetics of cancer.
The quite massive scale of operations, the high degree of standardization, the limited involve-
ment in research that characterize this kind of platform contrast with the more experimental
and expert settings that have been heretofore investigated. In our perspective, this calls for
careful analysis of the mundane processes through which clinical judgement and decisions
might become more distributed in such settings. This includes paying attention to the conflicts,
contestations, misunderstandings and negotiation processes through which a collective contour
is achieved in the production of diagnosis. In other words, we are less focused on highlighting
what is at stake in a new, ‘post-genomic’ regime of regulation of diagnosis, than in unpacking
and describing the content and everyday organization of what counts as diagnostic labour
when genomics exits expert contexts and enters more mundane settings with a strong pressure
for clinical productivity.
Settings and methods
In the early 2000s, the European Medicines Agency (EMA) granted the first market authoriza-
tions to a new family of cancer drugs, targeting tumours selected on their molecular (mostly
genetic) characteristics. In 2006 in France, the National Cancer Institute (INCa) launched a
State-funded programme which resulted in the setting up in French university hospitals and
cancer centres of 28 ‘platforms for molecular genetics of cancer’ (Nowak et al. 2012). Each
platform was required to analyse all the samples collected from both their host institution and
neighbouring private pathology labs. The programme included a list of tests to be provided,
according to a handful of guidelines (Institut National du Cancer, 2012).
The Institute lacked both the financial and regulatory means to impose and control ways of
doing tumour molecular analyses all over the country. It therefore resorted to a policy based
on financial incentives to foster local innovation and collaboration. Hospitals were encouraged
to set up these platforms drawing on pre-existing technological, professional and organizational
resources, at the local level. Not all of these molecular genetic analyses were new, nor did
they all rely on cutting-edge technology. Loosely defined in the market authorizations, they
consisted in either looking for pre-specified translocations, deletions or amplifications of DNA
segments, or in testing for the presence of potential DNA mutations in a pre-defined set of
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genetic coding regions (exons). The INCa also advocated for the certification of routine labora-
tory practices but did not impose specific processes or technologies for the tasks to be per-
formed. The incentive policy of INCa thus relied on stimulation through the provision of
technology and on the assumption that local resources would be idiosyncratically rearranged
for making molecular genetics of cancer doable. As such, the scaling up of tumour genetics in
France implied organizational bricolage rather than straightforward implementation. This
situation has therefore been conducive to the emergence of multiple particular cases of local
practices of tumour genetics.
In this paper, we approach the scaling up of tumour genetics in France through the thorough
study of one such case. The findings presented here are drawn from a collective ethnographic
study conducted as part of a larger project on high-throughput genomics in the clinic. We pre-
sent and discuss data collected in 2014 and 2015 in one of the INCa ‘platforms for molecular
genetics of cancer’, located in a regional university hospital in South-East France (hereafter
‘the Platform’). We conducted in-depth interviews with 10 professionals involved in tumour
genetics in the hospital (administrative officers, head of the Platform, anatomopathologists,
biologists, etc.) The interviews were open-ended and explored the interviewees’ career path,
everyday work experience and views on the recent development of their centre and of tumour
genetics itself. We also observed the organization of everyday work on the Platform, including
activities in the anatomopathology lab, various tasks involving anatomopathologists, molecular
biologists and administrative personnel, as well as administrative and clinical staff meetings.
Data were organized using Atlas.ti, interview transcripts and observation notes were analysed
thematically.
Bricolage on the platform: organizing new circulations within a university hospital
In this middle-size French university hospital, the trajectory of biological samples on the new
Platform is mostly organized between actors previously involved in a variety of biological
characterizations of tumours. It all started in 2006, with the drafting of a proposal to the INCa
call by two local female doctors, one of them leading a cancer research group. The project
involved solid tumours as well as haematological malignancies. One of the authors explains
the structure of the proposal:
We had to rely on hospital-based skills, to show that we were already diagnosing, but at the
same time [we had to show] that we were strongly rooted in research units. The platform
[in the proposal] was centred on three types of tumours: [aside of malignant haemopathies,]
there were pulmonary tumours, which was Martine’s1 [second author of the proposal] activ-
ity, and there were cerebral tumours with Prof. Chapatte. – Platform coordinator (MD)
Once granted INCa funds, the team crafted the actual Platform by innovatively organizing the
circulations of samples and data. The Platform facilities are hosted by the hospital’s Biology
and Pathology Centre (hereafter BPC). Two main constraints make the backdrop of the every-
day operation on the platform. The first one pertains to topographical and institutional com-
plexity, since five different units, located on four different floors of the BPC building are
involved: the department of pathology (which includes a distinct molecular pathology unit),
the onco-haematology genetics unit, the biochemistry and biotherapies unit, and the molecular
biology facility. Noteworthily, the perimeter of the Platform is far from self-evident for the
actors themselves. The second constraint is time-related. Because results are required to pre-
scribe a treatment, most of the time for patients with metastatic cancers, producing them in a
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timely fashion has become a central issue. According to a recent INCa survey (Institut
National du Cancer, 2016), the median time lapse between mutation results delivery and pre-
scription is 18 days. This timeframe is to be compared with the several months routinely
awaited in clinical genetics.
More than 90% of the Platform’s activity involves processing solid tumour biopsies, in the
form of samples fixed in a paraffin block that start and end their journey within the Pathology
department. All paraffin blocks, whether sent by external pathology labs, prepared by local
anatomopathologists or extracted from the hospital archives, arrive at the desk before being
routed for subsequent analyses. The desk secretary is also in charge of preparing and sending
the final report to the prescribing clinician and pathology lab. In between these initial and final
steps, the sample is diffracted into a handful of slides and digital information. Its characteriza-
tion may require the intervention of three different units of the BPC for different aspects of
tumour analysis. First, the pathology lab may perform a protein immuno-histo-chemistry (IHC)
revelation. Second, the molecular pathology lab may proceed with DNA hybridisation (FISH)
and third, the molecular biology lab may conduct a DNA mutation analysis.
When IHC is required, technicians prepare slides and reveal them with various antibodies.
The coloured slides are read with a microscope by an anatomopathologist. For a characteriza-
tion of DNA amplification or translocation, other slides are prepared and hybridized with
immuno-fluorescent probes. The results are then analysed with a fluorescence microscope by a
biologist. For a characterization of the mutation pattern, slides are sent to the molecular biol-
ogy on the second floor. Technicians extract, quantify and amplify the DNA before sequencing
it, using a pyrosequencer. The sequences are then read and analysed by a biologist who
validates the pattern of mutations.
In practice, the processing of a tumour biopsy is less linear than it seems. The processes are
often conditional to each other: IHC tests will be performed only if the sequencing results war-
rant it, FISH analyses are only conducted on a subset of samples identified by sequencing and
IHC results. The work to triangulate results obtained with different technologies is critical. It
helps fostering trust in DNA-based techniques and analyses for actors not directly involved in
their conduct. However, it also generates work overload. This is particularly true for the anato-
mopathologists, potentially creating a bottleneck for the processing of all tumour samples in
the hospital.
Sometimes we cannot say whether [the result] is positive or negative, it is inconclusive, it is
intermediate, so we are glad to have other techniques that can move the diagnosis forward
[. . .] I think it is really the notion of complementarity that is interesting and it does not
cause us so many problems. [But] it takes more work, that’s clear. It is an addition to the
routine and the work that we had before – Anatomopathologist (MD)
Rather than merely involving DNA sequencing, tumour genetics should thus be considered as
a network of heterogeneous and complementary forms of biomolecular analyses, in which
DNA sequencing is embedded.
The storage, communication and circulation of a whole variety of other material resources
constitute important issues for tumour genetics in this routine hospital setting. People and tools
are required both to organize the circulations occurring within, from and towards the Platform
and to bring together the different tasks necessary to fulfil the Platform’s assignments. This
articulation work (Strauss 1985) includes aspects such as managing the stocks of consumables
and reagents, or negotiating schedules for equipment use. An eloquent example is the little
‘paper technology’ (Krajewski 2011) that proved decisive in organizing the circulation of
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objects and information: a simple kraft envelope. As explained by one of the Platform desk
secretaries, when she took her position, all the important artefacts were scattered:
When I arrived here [. . .] the tissue block was on its own, the lab techniques [results] on
their own, the patient’s file was on its own, everything kept separate. (. . .) Some things were
lost and never recovered, incidentally. . . The idea behind the kraft envelope is that when a
sample arrives with the clinician’s prescription, I make a record, and I put everything in the
kraft envelope and it stays there, always. – Platform Desk Secretary
This dispersal appeared as a serious issue, endangering the necessary final gathering of slides
and results. This envelope is a striking illustration of the seemingly mundane activities and
tools that make up articulation work and allow collaboration to take place between the profes-
sionals that contribute to the Platform.
Another example is given by the computer information system for data storage and manage-
ment on the Platform. The pathology department has long been using a different system from
that used by other departments. As one of the administrative officers puts it: ‘[the software
applications] don’t talk to each other [. . .] one is like jihadists and the other is Jewish funda-
mentalists’. Since changing habits or software would have been too costly, the two systems
are used in parallel and the desk secretary enters all initial information on samples twice.
When needed, she pastes results from one system to the other or to an external file. This man-
ual intervention helps overcoming the disruption in the circulation of the data, but it also cre-
ates a notable risk of error: the secretary and the clinician responsible for the analyses must be
very watchful over the final results. Here again, articulation work appears as a necessary con-
dition for the smooth functioning of the heterogeneous biomolecular analysis network that
makes up tumour genetics on the Platform.
Making tumour genetics: a new technological and epistemic space alongside clinical
genetics
Given the extended presence of clinical genetics, including oncogenetics (Bourret et al. 2006),
within French cancer centres and university hospitals, one could have expected these rear-
rangements to be conducted in close association with local experts in genetics for the clinic.
Yet, in the case we investigated, tumour genetics thrives alongside clinical genetics rather than
in close cooperation with it. The interactions between germline genetics and tumour genetics
mainly consist in the pooling of resources: the fancier, next-generation sequencing (NGS)
machines were bought thanks to a national call directed to germline genetics of rare diseases,
and an NGS engineer was recruited on a position jointly funded by INCa and the clinical
genetics department.
The will [of mutualising] comes from the people here [. . .] With equipment in the state it was
and the needs now, this has become a necessity, because in the NGS era, machines cost a for-
tune. The purchase of the device is only 10%, roughly, of what has to be done. In order to make
a diagnosis in high-throughput genetics, one needs a strong bioinformatics backdrop, servers. . .
So, [mutualising] becomes a necessity. – Head of clinical genetics department (PhD)
Technical and cost-related constraints of NGS rather than clinical expertise were central moti-
vations for this policy, which implied intense negotiations regarding the conditions for sharing
data storage, the expertise of the NGS engineer, and access to machines.
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For many health professionals outside the Platform, the existence of a space shared by both
tumour and clinical geneticists – also referred to as a ‘NGS platform’ – contributes to the dou-
ble impression that ‘genetics’ is pervasive and ubiquitous; and that the Platform is somehow a
further manifestation of traditional clinical genetics. One of the platform professionals
explained:
We get this kind of questions: ‘we’re told about genetics in anatomopathology, in biochem-
istry, [in obs and gynae, paediatrics], what does it mean? You are all doing the same thing.’
– Biologist (PhD)
However, despite this blurriness and apparent similarity to untrained eyes, tumour and clinical
genetics markedly differ, when it comes to diagnostic labour itself. Contrasting a genetic anal-
ysis in tumour genetics (KRAS) and in oncogenetics (BRCA), the Platform coordinator points
to a twofold discrepancy:
The big difference is that with KRAS, we search for a mutation at a precise location. It’s
there or it’s not there. It’s binary. With BRCA, the mutation can be all over the gene and
some have no consequence, they’re not even a mutation. Others are deleterious and others
are unknown. This means that these mutations must be analysed by the scientists to evaluate
their consequences, either in vitro or with segregation analyses in families. There is a whole
circuit of work to validate mutations or not. Each family may have a distinct mutation. It is
completely different with KRAS, where we search exon 12 for a known mutation. There
may be many other mutations in the gene but we don’t care. – Platform Coordinator (MD)
First, in many cases, the production of a genetically informed diagnosis of disease (or of dis-
ease risk) requires the characterization of an entire gene or gene region, in order to either iden-
tify mutations or rule out their presence. As new mutations are regularly described, this search
has to be exploratory and often requires a specific expertise on the gene studied. In tumour
genetics, as it is performed in the Platform, the molecular characterization follows a different
path. All the mutations searched for are part of a pre-defined set. Each and every sample can
thus be processed and analysed in the same manner. No expert knowledge of the scrutinized
genes is required. Rather, technical dexterity and technology-oriented know-how are needed:
the initial steps to extract and prepare the DNA from a sample may involve a particular techni-
cal treatment; the final interpretation of the sequencing results may also require precise analyti-
cal skills, such as those of a PhD in biological sciences. This simplification and
standardization of the molecular genetic characterization process is essential: it is a crucial con-
dition to handle an increasing number of samples in a much shorter timeframe.
Second, as analysed by Bourret and Rabeharisoa (2008), in clinical genetics, diagnostic
work consists in simultaneously producing the clinical relevance and the biological signifi-
cance of mutations. These two tasks are intrinsically linked. The constitution of large mutation
databases, which have become central tools, has not fundamentally changed the nature of diag-
nostic labour (Timmermans 2015). The triangulation work between the clinic and the biology
remains unescapable.
What the type of tumour genetics performed in the Platform accomplishes is to add a further
step in the division of diagnostic labour. Work is restricted here to the molecular characterisa-
tion of mutations. The evaluation of their effects – i.e. their capacity to guide treatment deci-
sion – is not produced locally but taken for granted, resulting from market authorizations
issued by the EMA and completed by national directives published by the National Agency
for Drug Safety or by the INCa.
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For colon cancer, we used to sequence KRAS exon 2. The market authorization changed
last summer [. . .] Instead of analysing a single exon, we had to analyse six. Organizing such
a change in the lab is rather complicated. – Molecular Biologist (PhD)
While insisting on the technical and organizational constraints created by this loss of auton-
omy, this anecdote illustrates the new dependence on external decision bodies in charge of
defining mutation values, for the persons in charge of diagnostic labour. These two activities
that make up diagnostic work are therefore uncoupled and conducted by different actors in dif-
ferent places. This transformation, far from being straightforward, is met with resistances and
doubts, such as those expressed here:
It [tumour genetics] has to become true genetics. Even if we are not doing germline genet-
ics, it is necessary that germline genetics skills become available within somatic genetic
platforms. [. . .] For me, with advances in NGS, the link with genetics is mandatory because
there is a risk with the interpretation of results. [. . .] Germline and somatic genetics, at some
point, have to meet and these molecular genetics platforms, they must really stay genetic.
– Platform Coordinator (MD)
In this vision of future developments, the Platform coordinator criticizes, from both a practical
and scientific perspective, the distinction between two types of genetics: one that is deemed
able to accommodate a decoupling of diagnostic tasks – i.e. tumour genetics as currently per-
formed on the Platform – and another that cannot – i.e. germline genetics.
Meanings of molecular genetics: f(r)ictions in the practices of tumour profiling
The introduction of genomic characterization of tumours in the hospital has undoubtedly
contributed to make molecular biology more visible and legitimate in clinical settings. The cir-
culation and use of resources in the Platform – especially INCa funds – play an important role
in helping molecular biology gain recognition as a decisive link in the chain of clinical judge-
ment. However, this growing importance is often the source of tensions between professionals,
especially between pathologists and molecular biologists. Anatomopathologists, as medical
doctors, have historically been key players in the production of cancer diagnosis (L€owy 2010).
To this day, it is required that they examine all tumour samples, and they are responsible for
signing the final report. The “molecularisation” of diagnosis through sequencing has brought
along a few changes in their professional domain, though. For instance, consequently to the
creation of the Platform, a molecular biologist with expertise in cancer research, molecular
genetics and histology has been recruited within the pathology department. As a “molecular
pathologist” who holds a PhD but is not a medical doctor, she occupies an uneasy professional
space, and embodies some of the professional frictions between pathology and molecular
biology.
While pathologists advocate for a culture of diagnostic responsibility, molecular biologists
lament the shallow understanding of the underlying biological mechanisms among their pathol-
ogist colleagues. Both of these views are framed around each other’s expertise. Here is a
pathologist’s view:
In anatomopathology it’s not like in biology. Because in biology, outcomes are assays, and
assays, and assays. They just click on a button: there is someone, everyday, who is in
charge of doing the validation and that’s it. So, maybe, there’s one [result] that comes out
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red, ‘beware, it’s damn high’, maybe they look at it, but otherwise, no. Whereas we
[anatomopathologists], we speak, we express ourselves, in the end there is a diagnosis.
We’d better not miss a typo. – Anatomopathologist (MD)
A biologist’s perspective makes an interesting counterpoint. She considers molecular biology
an important shift in oncology and emphasizes the assets of her own expertise:
Molecular biology is the future of [anatomopathology] [. . .] Although I’m a molecular
biologist and not a medical doctor, I think my diagnosis is more reliable than [that of] a
pathologist who is not trained in molecular biology and who won’t even look for
information about the direction of gene transcription in order to correctly interpret a case. –
Biologist (PhD)
These professional tensions point to different ways of understanding what diagnosis and
tumour characterization mean and entail. In the anatomopathologists’ perspective, diagnosis
belongs to their professional jurisdiction. Through their professional identity, practices and dis-
course, they manifest an acute awareness of the oftentimes dizzying consequences their diag-
nosis may have on patients’ lives. They therefore embody an attention to the clinical
dimension of diagnosis, and feel bound by its consequences. This culture of responsibility ori-
ented towards diagnosis tends to be contrasted with the culture displayed by molecular biolo-
gists. The technological and scientific complexity underpinning their practices has become so
important – especially as regards the management and interpretation of genomic data – that it
is no longer entrusted to technicians alone, and requires extensive biological knowledge and
expertise. As a result, molecular biologists are foremost concerned by issues of accuracy and
correct interpretation, both in their technological and biological dimensions. Ultimately, these
concerns tend to take precedence over the clinical dimension. Novel tumour profiling practices
therefore call into question what it means to make a diagnosis, what makes a diagnosis reli-
able, and what professional responsibility entails.
Besides these professional debates, another type of friction is related to the challenges posed
by the introduction of new technologies, protocols and regulations in the Platform’s routine
operation. We already mentioned the regular updates in the mutations that must be searched
for in a given gene. Another good illustration is the switch to ‘true’ NGS that was slowly
being implemented during our fieldwork. As explained by a molecular biologist in charge of
the sequencing of tumour samples, the pressure to rapidly adopt new and high-tech machines
was confronted with the local needs and means available to support next-generation sequenc-
ing activities:
Our routine pyrosequencing technique with the Qiagen [sequencer] is not NGS. [. . .] It’s
not sequencing in which we read the whole sequence, we only look for targeted mutations.
[We made this choice] because of sensitivity issues, [this sequencer] can detect something
as low as 10% of mutations, which is good for tumour samples containing few tumour cells.
We’ve started NGS, and we’ve had an [Ion Torrent] PGM for more than a year now. [. . .]
It’s very impressive from a technical standpoint, it’s a beautiful machine, very sophisticated,
but its preparation is very tedious for the technicians. – Molecular Biologist (PhD)
The NGS manager explains that part of her work involves dealing with the potential disrup-
tions brought about by frequent updates in the protocol. These disruptions arise from the insta-
bility of these novel technologies, over time and in practice:
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Originally, the protocol would be updated each and every month. Now it’s more like every
six months. These technologies move a lot. It’s what makes them difficult to manage on a
day-to-day basis in diagnostics. The machines are new, and prone to technical problems.
[. . .] Updates in the protocol entail changes in the technical procedures, in the machines, in
the software for analysis. . . – NGS Manager (PhD)
As one can imagine, all the modifications that follow updates in the protocol impact the orga-
nization of work. Finding the right balance between the array of available sequencing tech-
nologies and a robust technological system that gets the job done in a timely and reliable
fashion is therefore another dimension of the frictions that surround the practices of tumour
profiling. Here, the type of friction involved is akin to Edwards’ metaphor of ‘data friction’,
i.e. the costly processes – in time, energy and human attention – that take place at the inter-
faces between groups, organizations, and machines across which data must move (Edwards
2010, Edwards et al. 2011).
The frictions of the kinds described above exemplify the relative instability of the technolo-
gies as well as the plurality of meanings and purposes ascribed to tumour profiling practices in
routinised hospital settings. Our observations show that these tensions give rise in return to a
series of negotiations and arrangements that ensure the partial integration and alignment of the
processes required for the production of a valid diagnosis. The drafting of the final report plays
an important role in this regard.
As recommended by the INCa, it consists of a single document to be sent to the prescribing
clinician, which combines the results and analyses provided by pathologists and molecular
biologists. The results are validated by the professionals who obtained them: the supervising
molecular biologist (sequencing results), the molecular pathologist (FISH results), or the anato-
mopathologist (IHC results). This document therefore contains data obtained through different
techniques, provided by different services and travelling through two distinct computer infor-
mation systems. Depending on the analyses conducted, the report can therefore consist of up
to three separate ‘parts’ and signatures, which are copied and pasted by the Platform desk sec-
retary from each of the two software applications into a single and final electronic document.
Far from being straightforward, the finalization of this document is subjected to careful adjust-
ments which reflect various stakes in terms of responsiveness, distribution of expertise and
responsibility, and validation processes.
The main issue at stake is the final validating signature, which consists in a mouse click
and attributes the responsibility of the entire process to the professional who performs this
final click. National regulations currently lead to the anatomopathologists being these profes-
sionals, i.e. the ones who are held responsible for the entire diagnosis. The view of one of the
molecular biologists emphasizes the stakes of expertise around this report:
What’s ludicrous [in the final report process] is that the [anatomopathologists], first don’t
have time to go back and check everything. And I am the molecular biologist; in this mat-
ter, the one who knows how to do [this technique], is me. Therefore I am the one who signs
my result. It must then be countersigned by an anapath. But what is the most dangerous? A
molecular biologist who is not an anapath but understands the technique and is able to inter-
pret, or an anapath who does not understand anything but simply because he’s an anapath,
is allowed to sign for a result? – Biologist (PhD)
This final report both materializes the professional and technological frictions, and contributes
to overcome them, by performing and sustaining a necessary fiction. Indeed, the linear way in
which the report is framed, and the formal oversight delegated to anatomopathologists in the
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process meet the social expectations of what diagnosis should be about – i.e. something per-
formed by a medical doctor –, all the while keeping trace of information coming both from
histology-based characterization of tumours and molecular tumour profiling. The fiction here is
that the diagnosis has been produced by a clinician, according to individualized clinical data
and concerns – age, sex, natural history of disease, socioeconomic conditions of the patients,
etc. –, while the therapeutic decision ultimately rests on solely molecular criteria.
Another necessary fiction on the Platform pertains to the ‘purity’ of tumour DNA itself – a
target that is almost impossible to achieve in practice, according to the actors. Biopsy samples
are indeed never thoroughly tumoural, since the location of the metastases may be difficult to
reach and tumour cells are often intertwined with non-tumour cells. This issue is well
acknowledged and receives particular attention. The initial task performed by pathologists
when a sample enters the Platform consists in evaluating the proportion of tumour cells it con-
tains. Samples with a proportion below 20% are not supposed to be further analysed. Yet, as
noted by one of the Platform’s biologists:
We receive many samples below 20% but we give them a try anyway. If I find a mutation,
I report it. If I can’t detect any, I say that there is a risk of false negative. For me. . . I can’t
say that I won’t process a sample. If it was sent to me, it must be that, for this patient, there
is no other choice. . .And we also know that the percentage of tumour cells may vary
depending on the pathologist. . . – Biologist (PhD)
Furthermore, no preliminary filter is applied to select only tumour cells when extracting the
DNA from a sample. The DNA to be characterized is thus a mixture of germline and tumour
DNA. In such a population of DNA sequences, a mutation of interest is not simply present or
absent, but detected in a certain proportion of sequences. Its tumoural origin is never ques-
tioned but taken for granted. The fiction here is that the DNA analysed is not germinal DNA
but a degenerate version of it, sufficiently differing as to not fall under legal regulations. The
genetic analyses can thus be conducted outside and beyond the realm of properly authorized
geneticists, in labs not fulfilling the standards set by the National Biomedicine Agency to con-
duct germinal DNA analyses, and without following the information and consent procedure
otherwise mandatory.
Discussion and conclusion
In this paper, we have studied the introduction of tumour genetics in a dedicated platform hosted
by a French university hospital. Contrarily to clinical genetics (including oncogenetics) settings,
the diagnostic labour performed on the Platform does not primarily rely on categorical work
(Latimer et al. 2006) articulating genetic and medical knowledge. Indeed, the meaning of the
mutations identified, i.e. the evaluation of their capacity to guide treatment decisions, is not
assessed locally but results from external regulatory decisions. No bioclinical collective is locally
mobilized to carry out the clinical work and produce the meaning and relevance of mutations.
Yet, what is being performed here is still diagnostic labour, directed towards the production
of a treatment decision, based on molecular analyses of tumour samples and performed in a
timeframe compatible with urgent care. The issues at stake are more classically related to the
organization of work in a complex biomedical context. Indeed, our ethnography shows that
tumour genetics on the Platform cannot be reduced to DNA sequencing alone, but is rather
embedded in a network of heterogeneous and complementary forms of biomolecular tools and
analyses, that mobilizes a variety of specialists, with their own skills and professional cultures.
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This complex sociotechnical network produces important professional and technological
frictions, that reveal the plurality of meanings and purposes ascribed to tumour profiling
practices in routinised hospital settings. In particular, we show the contrast between molecular
biologists and medical pathologists, their perception of what makes a diagnosis reliable and
what the locus and focus of their professional responsibility consist in.
We have described the challenges posed by introducing new technologies, protocols and
regulations – initially developed in research settings – in routine operations where the priority
is to rely on a robust technological system that gets the job done in a timely and reliable fash-
ion. Our study further illustrates the sense of urgency associated with this type of clinical diag-
nosis. This is shared by all the professionals involved, is tangible in a series of negotiations
and arrangements, and fosters the deliberate adoption of different fictions that help overcoming
the frictions, in order to perform molecular diagnoses. These fictions concern the nature of the
biological material to be analysed (tumour DNA) as well as the meaning of the diagnostic
work collectively undertaken.
In her exploration of how different versions of a disease (atherosclerosis) somehow manage
to ‘hang together’ in the hospital, Mol (2002) insists on the importance and relevance of
various modes of coordination. They include the circulation of paperwork, the addition and
calibration of diagnostic test outcomes, the representation of numbers and data through formu-
lae and pictures, and the pluridisciplinary meetings where specialists collectively discuss the
diagnosis and treatment of individual cases (Mol 2002, 84). In her view, these practices, and
the way they sustain ‘coherence-in-tension’ (Mol 2002, 84), partake largely in making clinical
work doable. The use of fictions we describe in this paper resonates with this understanding of
coordination processes in the hospital – with the additional challenge that what must be made
to ‘hang together’ here, are clinical and biological enactments of cancer. However, these fic-
tions do not simply function as an additional mode of coordination. Rather, we see them as a
way of negotiating the meaning and legitimacy of existing work practices (such as drawing
together different diagnostic tests into a single report), the authority of those who perform
them (pathologists, clinicians, medical biologists, technicians and so on) and the kinds of
knowledge they use. These fictions are therefore arrangements that distribute and order differ-
ent professional and epistemic rationalities in order to make tumour genetics doable.
We do not mean to suggest here that the form of diagnostic labour observed in the Platform,
not primarily relying on categorical work, is an intrinsic property of tumour genetics. Studies
have precisely discussed the sociotechnical regime associated with tumour genetics, in which
mutations have become obligatory passage points (Latour 1988) for the prescription of a given
drug to patients, and are referred to as ‘actionable’ by both oncologists (Carr et al. 2016) and
analysts (Cambrosio et al. 2014, Nelson et al. 2013). Relying on detailed descriptions of
experimental settings, mainly clinical trials, these studies have shown how the work performed
by bioclinical collectives in which clinicians, biologists, bio-informaticians and bio-statisticians
make up hypotheses regarding the values of mutations, constitutes a particular mode of drug-
oriented categorical work.
The point we wish to make here is that in routine hospital contexts, the diagnostic labour
associated with tumour genetics can be notably different from that observed in experimental or
expert settings. First, the particular organization of the drug market with its strong institutional
regulation has introduced the possibility, and potentially the necessity, for a temporal disarticu-
lation between the two tasks required for diagnostic work in genetics. The division of labour
between molecular genetics characterization and its clinical implications is taken a step further.
Fixed by market authorizations, the clinical value of a mutation is no longer produced locally
by bioclinical collectives. Second, far from being an anomaly, this new division of labour
appears as a driving force allowing the rise in clinical productivity required by this new
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function assigned to genetics; namely, to guide the prescription of drugs for common diseases.
The resulting work required to make a diagnosis can indeed be performed without resorting to
expert bioclinical collectives, and outside the professional jurisdiction of clinical geneticists
(experts in ‘true genetics’). Provided the organization of adequate ways of distributing and
recollecting the different tasks, of circulating artefacts, information or financial resources,
significant flows of genetic analyses can routinely be managed by professionals with more
fragmented but complementary expertise.
We believe that this turn in the way genetics is embedded in the clinic should be considered
seriously, given its rising importance. With the regulation of uncertainty no longer performed
locally but largely delegated to other regulatory levels (market authorizations, guidelines or
technical standards), this new and yet massive context of use calls for a thorough reassessment
of the impacts of genomics on clinical discourses, practices and decisions.
Address for correspondence: Claire Beaudevin, Cermes3, campus CNRS, 7 rue Guy Môquet,
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